PRPO (Precipio) Net earnings per share (EPS TTM)

PRPO (Precipio, Inc) - company brandmark

Precipio, Inc. (PRPO) generates revenue through the sale of reagents and expert blood analyses for oncology centers. The company's average annual revenue per unit confirms the profit trend, with the value stabilizing at -0.64. Stability is ensured by a staff of elite pathologists protected from burnout. However, pricing power is limited by insurance caps, despite the possession of ICE-Cold PCR patents.

PRPO precipiodx.com Earnings per share for the last twelve months (07/04/2022 - 11/12/2026)

Metric breakdowns and analytics for Precipio Inc. (PRPO)

- current quotes and average value forecast:
Price Chart Precipio, Inc.|PRPO - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization Precipio, Inc.|PRPO - Enterprise Value
- business book valuation details:
Net Assets per Single Share Precipio|PRPO - Company Book Value|Market Cap to Net Assets Ratio precipiodx.com|PRPO - Company Assets
- debt level and financial liquidity data:
Debt to Equity Precipio, Inc.|PRPO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Precipio, Inc|PRPO - Company Total Debt Obligations|Debt to Book Capitalization Ratio Precipio, Inc.|PRPO - Long-Term Debt Volume|Company Short-Term Debt Precipio|Quick Liquidity precipiodx.com
- earnings and multiples data:
PRPO - Final Profit|Projected Future Earnings Precipio, Inc.|PRPO - Market Cap to Earnings|Forward P/E Multiple Precipio|PRPO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Precipio, Inc.|PRPO - Operating income before deduction of amortization|Earnings per share for the last twelve months Precipio|PRPO - Earnings per one share for the last 12 months|Quarterly EPS earnings growth precipiodx.com|PRPO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Precipio, Inc.
Fundamental company analysis:PRPO - Precipio, Inc.
Mass-produced product of Precipio Inc.

Net income per share over 12 months measures the actual return on each unit of capital, smoothing out short-term volatility. This metric assesses the business's ability to generate profit after all deductions. By analyzing the 12-month net income per share trend, an investor can see the effectiveness of ESG standard implementation and waste optimization in Precipio, Inc. (PRPO) diagnostics. Resource savings directly impact the bottom line, confirming the company's operational viability.

Competitors of Precipio, Inc.

CAI - Earnings per share for the last twelve months|GH (guardanthealth.com) - Earnings per share for the last 12 months|VCYT: Net earnings per share (EPS TTM)|Celcuity Inc (CELC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months GRAIL Corp|Earnings per share for the last twelve months MYGN|Net earnings per share for the last 12 months CSTL (Castle Biosciences)|BNR - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months VolitionRx VNRX|Net earnings per share for the last four quarters Biodesix Inc (BDSX)|Check-Cap Medical - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Mainz Biomed NV MYNZ|OncoCyte Corporation (OCX) - Earnings per share for the last twelve months